Management of Acute Gout Arthritis
For an acute gout flare, initiate treatment with corticosteroids, NSAIDs, or colchicine as first-line therapy, with corticosteroids preferred as the safest and most cost-effective option in patients without contraindications 1.
First-Line Anti-Inflammatory Treatment Options
All three medication classes are equally effective at reducing pain during acute gout flares, but they differ significantly in safety profiles and contraindications 1:
Corticosteroids (Preferred First-Line)
- Prednisolone 35 mg daily for 5 days is the evidence-based regimen 1
- Safest option with fewer adverse effects compared to NSAIDs 1
- Most cost-effective choice 1
- Contraindications: Systemic fungal infections, uncontrolled diabetes (relative)
- Short-term adverse effects: Transient hyperglycemia, mood changes, fluid retention 1
NSAIDs (Alternative First-Line)
- No NSAID is superior to another - indomethacin has no advantage over naproxen or ibuprofen 1
- Use any NSAID at full anti-inflammatory doses
- Contraindications: Renal disease, heart failure, cirrhosis, history of GI bleeding 1
- Adverse effects: Dyspepsia, GI perforation/ulcers/bleeding, renal impairment 1
Colchicine (Alternative First-Line)
- Low-dose regimen only: 1.2 mg followed by 0.6 mg one hour later 1
- This low-dose regimen is equally effective as high-dose but with significantly fewer GI side effects 1
- More expensive than corticosteroids or NSAIDs 1
- Contraindications: Severe renal or hepatic impairment, concurrent use of strong CYP3A4 inhibitors (clarithromycin, ketoconazole) or P-glycoprotein inhibitors 1
- Adverse effects: Diarrhea (first sign of toxicity - reduce dose immediately), nausea, vomiting 1, 2
- Dose reduction required in chronic kidney disease 2
Critical Timing Principle
Patients should be educated to self-initiate treatment within 12 hours of flare onset according to a pre-defined treatment plan 2. Early treatment is associated with better outcomes and shorter flare duration.
Urate-Lowering Therapy During Acute Flares
If urate-lowering therapy (ULT) is indicated, you can start it during the acute flare rather than waiting for resolution 3. This conditional recommendation is based on:
- Time efficiency and improved patient adherence 3
- Evidence showing ULT initiation during flares does not prolong or worsen the flare 3
- Patient motivation is highest during symptomatic periods 3
However, always provide anti-inflammatory prophylaxis (colchicine, NSAIDs, or low-dose prednisone) when starting ULT and continue for 3-6 months 3.
When NOT to Start Long-Term ULT
Do not initiate urate-lowering therapy after a first gout attack or in patients with infrequent attacks (<2 per year) 1. The benefits of long-term ULT in these patients are unproven, and many will have no or infrequent recurrences 1.
Reserve ULT discussions for patients with:
- ≥2 gout flares per year
- Tophi present
- Chronic kidney disease
- Urolithiasis
- Radiographic evidence of gouty arthropathy 1, 4
Second-Line Options
IL-1 inhibitors can be considered for flares refractory to or contraindicated with all first-line agents 5, 2. These require:
- Screening for active infection (absolute contraindication)
- Monitoring neutrophil counts 2
- Significantly higher cost
Common Pitfalls to Avoid
Do not use high-dose colchicine regimens - they offer no additional benefit and cause significantly more GI toxicity 1
Do not assume indomethacin is superior - this is a persistent myth without evidence 1
Do not delay treatment - waiting reduces efficacy; educate patients to self-treat immediately 2
Do not forget drug interactions with colchicine - particularly dangerous with CYP3A4 inhibitors in patients with any renal impairment 1
Screen comorbidities carefully - older patients often have multiple contraindications to standard therapies 6